Ophthotech Corp (OPHT) on Watch After Regeneron (REGN) Reports Eylea/Rinucumab Combo Data

September 30, 2016 8:05 AM EDT
Get Alerts OPTH Hot Sheet
Trade OPTH Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Ophthotech Corp (NASDAQ: OPHT) was in focus Friday morning after Regeneron (NASDAQ: REGN) announced topline results from its Phase 2 CAPELLA study evaluating Eylea (aflibercept) co-formulated with rinucumab in patients with neovascular age-related macular degeneration (wet AMD).

Ophthotech traded lower pre-market.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Add Your Comment